Your search returned 2 results.

Results
	1.	Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. MedStar authors: Atkins, Francis Garcia, Carlos Van Nostrand, Douglas PMID: 28104741 Year: 2017 Citation: Journal of Nuclear Medicine. 58(7):1146-1154, 2017 Jul Institution: MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Medline publication type: Journal Article Form of publication: Journal Article All authors: Atkins F, Garcia C, Hobbs RF, Huang K, Plyku D, Sgouros G, Van Nostrand D DOI: https://dx.doi.org/10.2967/jnumed.116.179366 Add to cart (remove)
	2.	Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?. MedStar authors: Atkins, Francis Burman, Kenneth Garcia, Carlos Khorjekar, Gauri R Mete, Mihriye Moreau, Shari O'Neil, Jeff Orquiza, Michael H Van Nostrand, Douglas Wartofsky, Leonard PMID: 24820222 Citation: Thyroid. 24(9):1394-9, 2014 Sep. Institution: MedStar Health Research Institute MedStar Washington Hospital Center Department: Medicine/Endocrinology Medicine/Nuclear Medicine Medline publication type: Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins FB, Burman K, Garcia C, Khorjekar GR, Mete M, Moreau S, O'Neil J, Orquiza MH, Van Nostrand D, Wartofsky L DOI: http://dx.doi.org/10.1089/thy.2013.0713 Add to cart (remove)

Powered by Koha